Alpha1-antitrypsin Deficiency Clinical Trial
Official title:
A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
The study was a Phase 1B/2A, uncontrolled, open-label, single-center study in individuals with congenital AAT (alpha 1-antitrypsin) deficiency. A baseline bronchoscopy with bronchoalveolar lavage (BAL) was performed 3 to a maximum of 4 weeks prior to the first administration of study drug. Fifteen eligible subjects were randomized to receive 1 of 3 dosing regimens of rAAT (100 mg daily, 100 mg twice daily, or 200 mg daily) administered via nebulization for 7 consecutive days. A post-treatment nadir BAL was obtained on study Day 8 (12 hours after last dose for subjects who receive drug therapy twice daily and 24 hours after the last dose for subjects who receive study product daily). BALs were conducted in the same lung lobe/segment. Follow-up visits took place on Day 15 and Day 36.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02282527 -
A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency
|
Phase 2/Phase 3 | |
Terminated |
NCT02722304 -
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
|
Phase 3 | |
Withdrawn |
NCT04440488 -
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
|
Phase 4 | |
Completed |
NCT02525861 -
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
|
Phase 3 | |
Recruiting |
NCT05677971 -
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
|
Phase 3 | |
Recruiting |
NCT06165341 -
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
|
Phase 3 | |
Terminated |
NCT00313144 -
Aralast alpha1-proteinase Inhibitor Surveillance Study
|
Phase 4 | |
Completed |
NCT01651351 -
GLASSIA Infusion Rate Study
|
Phase 4 | |
Completed |
NCT02870348 -
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
|
Phase 1/Phase 2 | |
Completed |
NCT02870309 -
Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
Completed |
NCT04474197 -
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
|
Phase 2 | |
Completed |
NCT00161707 -
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05466747 -
A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema
|
Phase 4 | |
Enrolling by invitation |
NCT05899673 -
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
|
Phase 3 | |
Recruiting |
NCT04722887 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
Recruiting |
NCT02929940 -
Liver Disease in Patients With alpha1-antitrypsin Deficiency
|
N/A |